December 31 For the three months finished, 2010, Alexion Pharmaceuticals, Inc.0 million, reflecting strong additions of new patients, compared to $110.6 million for the same period in ’09 2009. We served significantly greater numbers of sufferers with PNH in our core territories of the U.S.S. , EU and Japan , is the only drug particularly indicated for the treating individuals with paroxysmal nocturnal hemoglobinuria , a rare, debilitating and life-threatening bloodstream disease. Historically, Alexion’s non-GAAP working results have been equal to GAAP operating results less the impact of share-based payment and taxes that are not payable in cash . Additionally, acquisition-related expenses are excluded from non-GAAP results. The following summary desk is provided for investors’ convenience.This expands our analytical features, accelerates our procedures and enables us to create higher quality information, which not only provides us with an increase of confidence in the total results, but also our clients in the pharmaceutical industry. LipidView Software program is another example of how AB SCIEX delivers software program that manages total workflow solutions for medication discovery and biomarker analysis. This new tool will help researchers expand the study of lipids within an emerging field within systems biology.